Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.15 -2.5%	$2.29	$1.89 ▼ $3.68	$940.04M	0.36	3.13 million shs	8.04 million shs
CVAC CureVac	$5.60 +37.6%	$3.70	$2.37 ▼ $5.71	$1.26B	2.49	785,499 shs	22.92 million shs
OCS Oculis	$19.68 +0.3%	$18.17	$10.79 ▼ $23.08	$859.27M	0.35	44,892 shs	19,651 shs
VYGR Voyager Therapeutics	$3.60 +6.5%	$3.25	$2.65 ▼ $9.55	$199.21M	0.82	474,448 shs	943,490 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+6.95%	+33.47%	+56.80%	+34.58%	-5.83%
CVAC CureVac	-4.68%	-8.33%	+12.43%	+34.32%	-4.24%
OCS Oculis	-0.81%	+2.51%	+11.53%	+4.97%	+64.68%
VYGR Voyager Therapeutics	-2.31%	+1.81%	+0.90%	-16.95%	-61.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.6479 of 5 stars	3.4	1.0	0.0	3.2	3.3	0.6
CVAC CureVac	4.4846 of 5 stars	3.5	4.0	4.8	3.4	0.0	1.3
OCS Oculis	1.7833 of 5 stars	3.5	3.0	0.0	1.1	0.0	0.6
VYGR Voyager Therapeutics	4.4289 of 5 stars	3.6	1.0	4.6	3.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	164.55% Upside
CVAC CureVac	3.00	Buy	$11.00	96.43% Upside
OCS Oculis	3.00	Buy	$35.33	79.54% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	271.94% Upside

Current Analyst Ratings Breakdown

Latest VYGR, OCS, CVAC, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/9/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
4/30/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/17/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $32.00
4/17/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/16/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $5.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/13/2025	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$37.00 ➝ $41.00
3/13/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/13/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $29.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$23.11M	40.67	N/A	N/A	$3.97 per share	0.79
CVAC CureVac	$523.70M	2.40	N/A	N/A	$2.50 per share	2.24
OCS Oculis	$980K	876.80	N/A	N/A	$2.87 per share	6.86
VYGR Voyager Therapeutics	$66.96M	2.98	$2.55 per share	1.41	$5.37 per share	0.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.40M	-$0.56	N/A	N/A	N/A	-533.32%	-15.73%	-12.22%	8/5/2025 (Estimated)
CVAC CureVac	-$281.58M	$0.92	10.18	N/A	N/A	20.72%	21.98%	15.72%	8/13/2025 (Estimated)
OCS Oculis	-$98.92M	-$2.64	N/A	N/A	N/A	-8,043.28%	-71.31%	-56.85%	8/26/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	5.07	N/A	N/A	15.80%	8.33%	6.15%	8/5/2025 (Estimated)

Latest VYGR, OCS, CVAC, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	9.34	9.34
CVAC CureVac	0.05	6.20	6.19
OCS Oculis	0.01	4.02	4.02
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CVAC CureVac	17.26%
OCS Oculis	22.30%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CVAC CureVac	2.15%
OCS Oculis	N/A
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.66 million	Optionable
CVAC CureVac	880	224.34 million	219.07 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.15 million	Optionable

VYGR, OCS, CVAC, and ABCL Headlines

Recent News About These Companies

Space Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss Expansion

June 12 at 12:08 PM | devdiscourse.com

Voyager Technologies Rises in Debut, Signaling Improving IPO Market

June 12 at 7:07 AM | msn.com

Cantor Fitzgerald Estimates VYGR FY2026 Earnings

June 12 at 2:23 AM | americanbankingnews.com

Voyager soars 82% on first day of trading as defense tech booms

June 12 at 2:06 AM | msn.com

Investor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOs

June 11 at 9:05 PM | msn.com

Voyager Technologies' Shares More Than Double in NYSE Debut

June 11 at 4:04 PM | marketwatch.com

Voyager Technologies Shares Soar In Market Debut

June 11 at 4:04 PM | news.crunchbase.com

Space tech firm Voyager valued at $3.8 billion as shares surge in NYSE debut

June 11 at 4:04 PM | aol.com

Voyager raises $383 million from upsized IPO

June 11 at 4:04 PM | spacenews.com

Space and defense tech firm Voyager raises $382.8 million in IPO

June 11 at 4:04 PM | fastcompany.com

Voyager Technologies Valued at $3.8 Billion in Stellar NYSE Debut

June 11 at 4:04 PM | msn.com

Voyager Technologies’ IPO shows investors are still hot on space stocks, despite a mixed history

June 11 at 4:04 PM | marketwatch.com

Voyager Announces Pricing of Initial Public Offering

June 10 at 8:45 PM | bakersfield.com

Brokers Issue Forecasts for VYGR FY2026 Earnings

June 10 at 8:30 AM | marketbeat.com

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 10 at 7:00 AM | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by Analysts

June 10 at 1:45 AM | americanbankingnews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

June 10 at 1:42 AM | marketbeat.com

Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)

June 7, 2025 | seekingalpha.com

Voyager Technologies, Inc. Announces Launch of Initial Public Offering

June 3, 2025 | finanznachrichten.de

Space Firm Voyager Technologies Seeks $1.6 Billion Valuation in IPO

June 2, 2025 | theinformation.com

2001: A Space Odyssey's balletic waltz to be beamed to Voyager 1

May 27, 2025 | newatlas.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, OCS, CVAC, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.15 -0.08 (-2.48%)

As of 04:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

CureVac NASDAQ:CVAC

$5.60 +1.53 (+37.59%)

As of 04:00 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Oculis NASDAQ:OCS

$19.68 +0.05 (+0.25%)

As of 03:59 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Voyager Therapeutics NASDAQ:VYGR

$3.60 +0.22 (+6.51%)

As of 04:00 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time